BACKGROUND The morpheaform subtype of basal cell carcinoma (BCC) often presents a diagnostic histological challenge, and its true margin may be difficult to determine with accuracy. This tumor may also be difficult to distinguish from other adnexal neoplasms having a benign clinical course. Previous work has shown that cytokeratin 17 (CK17 or K17) expression is high in BCC.
B asal cell carcinoma (BCC) normally does not present substantial diagnostic difficulties from a histologic standpoint, but certain BCC variants, such as the morpheaform type, can be difficult to diagnose or distinguish from other morphologically similar entities, such as desmoplastic trichoepithelioma. Dermal strands of tumor or isolated single tumor cells may also be difficult to detect. It would be useful to establish promising markers that would ensure complete removal of tumors from sensitive areas such as on the face, around the eyes, and on the ears. There is background information suggesting that cytokeratin 17 (CK17 or K17) may be such a useful marker, [1] [2] [3] [4] [5] [6] but no studies have addressed the usefulness of K17 in differential diagnosis and tumor detection. throughout human epithelia. There are two families of keratins, classified as type I or type II based on biochemical properties. Members from the two keratin families form obligate heteropolymers, meaning that a member from each family must be coexpressed to form a filament. 7, 8 Aside from providing structural support to epithelial cells, these filaments have been shown to be involved in cell signaling. Keratins can modulate the ability of cells to undergo apoptosis. 9, 10 Tong and colleagues have shown that, in mice, K17 modulates hair follicle cycling from anagen to catagen phases. K17 is normally expressed in palmoplantar keratinocytes and in the nail bed, hair follicle, and sebaceous and sweat glands. 11, 12 Concerning its presence in the hair follicle, K17 is found admixed with several other keratins throughout the medulla of the hair shaft. K17 expression is also found in the outer root sheath, but its presence is limited to the isthmus and lower portion of this structure. 12 K17 has also been found to be prominently expressed in human epidermal Merkel cell-rich sensory organs. 13 K17 has been shown to be inducible by wounding or injury, and it is found to be upregulated in hyperproliferative conditions such as psoriasis. [14] [15] [16] [17] Also, mutations in K17 can lead to a form of the rare disorder pachyonychia congenita, in which patients develop nail dystrophy, palmoplantar keratoderma, and other cutaneous findings associated with abnormal keratinization. 18, 19 It has also been shown that K17 expression is high in the epithelium of viral warts, 20 in oral squamous cell carcinoma, 21 and in lesions of cervical intraepithelial neoplasia (CIN). It has also been demonstrated that enhanced positivity for K17 immunostaining is significantly correlated with increasing lesional grade for CIN. 22 Meara and colleagues observed that K17 was overexpressed in odontogenic keratocysts. These cysts are locally destructive lesions of the jaw and are associated with the nevoid BCC syndrome (NBCC, Gorlin's syndrome). Also noted in that study was the finding that K17 immunostaining was stronger and more uniform in specimens from patients with NBCC than in those from patients without that condition. 23 BCC is the most common malignancy of the skin. 24 It is a peculiar neoplasm, with distinctive traits, in that it can undergo sustained local growth but is much less likely to metastasize, but the morpheaform or desmoplastic subtype of this tumor is notorious for being more aggressive, because it tends to invade the local tissues beyond the clinically apparent margins and to recur after excision. BCC develops almost exclusively on skin containing pilosebaceous units, with the face being a favored site. 24 This funding suggests that these anatomic locations may be home to a greater number of precursor or progenitor tumor cells. 24 Because cell activation and differentiation generally regulates keratin expression, it can be inferred that its expression may shed light on the differentiation trends of skin neoplasms. Several studies focused on keratin analysis have pointed to the hair follicle as the potential harbor of progenitor cells leading to BCC. [1] [2] [3] 25, 26 Moll and colleagues initially proposed that BCC is of follicular origin because of the presence of K17 in the pilosebaceous unit and in lesions of BCC. Furthermore, the expression of K17 in BCC has been noted in other studies. [1] [2] [3] [4] [5] [6] The presence of K17 has also been noted in other tumors of proposed follicular differentiation, such as trichilemmal carcinoma, 27 trichoblastoma, and trichoepithelioma. 6, 28, 29 Trichoblastoma and trichoepithelioma are adnexal neoplasms thought to display mostly follicular germinative differentiation. It is thought that trichoblastoma displays mostly follicular bulbar differentiation, and some feel that it represents an immature form of trichoepithelioma. The term desmoplastic trichoepithelioma refers to a variant of tumor with extensive dermal sclerosis. 30 As previously mentioned, these lesions can present a diagnostic challenge and mimic BCC clinically and histologically, but they generally do not carry the In this report, our aim was to confirm the expression of K17 across the subtypes of superficial, nodular, and morpheaform BCC variants. Specifically, our intent was to determine whether the moreaggressive morpheaform variant demonstrates a correspondingly higher expression of K17. Additionally, we sought to compare K17 immunostaining in BCC with that found in two other adnexal neoplasms of proposed follicular origin: trichoblastoma and desmoplastic trichoepithelioma.
Materials and Methods
The study was conducted in full compliance with institutional review board approval. Fifty paraffinembedded archived tissue samples from skin biopsy specimens (30 cases of BCC (10 cases of each aforementioned subtype), as well as 10 cases each of trichoblastoma and desmoplastic trichoepithelioma) were identified, and their tissue blocks were obtained. A dermatopathologist had previously diagnosed each case microscopically using standard hematoxylin and eosin (H&E) staining methods. The archived specimens were chosen in a sequential and unselective manner based on a pathology requisition number search. Histology and immunostaining were performed on all specimens simultaneously in the Department of Dermatology laboratory and in the Roger Williams Center of Biomedical Research Excellence Imaging Core (PI, V. Falanga). Four-micron-thick sections of formalin-fixed tissue were used for immunoperoxidase analysis. After baking at 37°C overnight, deparaffinization and rehydration were performed (100% xylene 94 for 3 minutes each, 100% ethanol 94 for 3 minutes each, and running water for 5 minutes). The sections were blocked for peroxidase activity with 1% hydrogen peroxide in methanol for 30 minutes and washed under running water for 5 minutes. The sections were pressurecooked (Biocare Medical, Concord, CA) for antigen retrieval at 123°C in citrate buffer (Target Retrieval Solution, DAKO, Carpinteria, CA). The sections were cooled for 15 minutes and transferred to phosphate buffered saline. The sections with CK17 (NCL-CK17 from Novocastra, Newcastle upon Tyne, UK) were incubated overnight at a 1:100 dilution at 4°C. The NCL-CK17 antibody reacts with the human cytokeratin intermediate filament protein (46 kD) identified as cytokeratin 17. The secondary antibody (Envision Mono K4007; DAKO) was applied for a 30-minute incubation. All incubations were performed in a humid chamber at room temperature. The slides were rinsed with Tris-buffered saline (TBS) between each incubation. The sections were developed using 3,3′-diaminobenzidine (DAB, Sigma Chemical Company, St. Louis, MO) as the substrate and counterstained with Mayer's hematoxylin. Human trachea was used as a positive control.
The K17 immunostained sections were examined using standard light microscopy and by comparing them to the H&E-stained sections. Photomicrographs were taken of the sections, and the results were analyzed using a scoring system for the extent and intensity of immunostaining (see below). One of the authors (VF) with full training in histologic methods and dermatopathology assessed the H&E and immunostaining.
To perform CK-17 immunostaining using frozen sections, we used a standard protocol. Mohs frozen sections were cut at 4 lm and fixed in cold acetone for 10 minutes. After being washed in TBS, sections were incubated in 3% hydrogen peroxide for 5 minutes to block the endogenous peroxidase activity. Nonspecific reactivity blocking was accomplished by incubating the sections in goat normal serum for 20 minutes. With no additional washing, the sections were incubated with the primary antibody (mouse antihuman CK17 from Dako) for 1 hour. Sections were then raised to remove excess antibody and subsequently incubated for 30 minutes with the secondary antibody (goat antimouse polymer-horse radish peroxidase, EnVision system, DAKO). Substrate DAB was used to develop the brown color, and hematoxylin was used for counterstaining.
Results
K17 immunostaining has been previously reported in tissue sections of mostly nodular BCC. [1] [2] [3] [4] [5] [6] In those previous reports, there was no attempt to analyze morpheaform BCC and its surgical margins, and no comparison was made with tumors with histologic overlaps with morpheaform BCC. Therefore, our first goal was to confirm K17 expression in our own sequential and unselected tissue samples of BCC. In addition, we wanted to compare the immunostaining presence and intensity in different variants of BCC, as well as in trichoblastoma and desmoplastic trichoepithelioma. Using archived tissues, we retrieved 10 unselected and sequential archived specimens for five tumor types or variants (categories): superficial BCC, nodular BCC, morpheaform BCC, desmoplastic trichoepithelioma, and trichoblastoma. In three of these categories of tumors, nine of 10 specimens were available for further analysis. This is because in one of each of those 10 specimens blocks there was lack of tumor upon further sectioning.
The sections were scored for intensity and extent of K17 immunostaining, as previously described (31) . Briefly, intensity of immunostaining was ranked on a scale of 0 to 3 (0 = absence of immunostaining, 1 = low, 2 = moderate, 3 = high). The extent of immunostaining was ranked on a scale of 0 to 3 (0 = absence of immunostaining, 1 = focal or <10% of cells, 2 = patchy or 11-75% of cells, 3 = diffuse or >75% of cells). One of the coauthors independently graded the specimens (VF; Table 1 ). Table 1 summarizes the overall immunostaining presence and intensity of morpheaform BCC and the other tumors that were investigated. The scores represent the means and standard errors of the mean. As shown in Table 1 , the mean intensity and extent of K17 immunostaining in superficial, nodular, and morpheaform BCC were more than two times as great as trichoblastoma and more than five times as great as desmoplastic trichoepithelioma. In particular, K17 expression scoring was statistically greater in morpheaform BCC than desmoplastic trichoepithelioma (Student t-test; p < .001). The differences in scoring between these two latter types of tumors and their variants with respect to K17 expression were dramatic. This can be seen in representative photomicrographs (Figures 1-4) and is described in detail in the legends.
K17 immunostaining was strongly positive in a diffuse pattern throughout the lesions of superficial BCC in 100% (n = 10) of the specimens analyzed. Figure 1A ,B show representative images from this group of specimens. K17 immunostaining was similarly positive in a diffuse pattern throughout the lesions of nodular BCC in 100% (n = 9) of the specimens analyzed. Figure 1C ,D show representative images from this group of tumors. An important novel goal of this work was to determine whether K17 immunostaining could identify and outline the dermal tumor strands or cells typical of morpheaform BCC. The reasons for this goal lie in the not-uncommon difficulties one encounters in the diagnosis and assessment of the extent of this tumor and the differential diagnosis from desmoplastic trichoepithelioma. We found that K17 may be a valuable marker for those purposes. K17 immunostaining was strongly positive throughout the lesions of morpheaform BCC in 100% (n = 9) of the specimens evaluated. These findings are shown in representative Figure 2A -D. We found that the K17 immunostaining could prove useful in identifying individual tumor cells located away from the morpheaform strands. This finding is illustrated by Figures 2E and 3D , where K17 immunostaining highlights individual cells in the dermis. We were able to detect these individual tumor cells away from the tumor strands in 78% (n = 9) of the specimens. Likewise, K17 immunostaining on frozen sections of morpheaform BCC taken during Mohs micrographic surgery was strongly positive, and small tumor strands and cords were readily apparent ( Figure 5 ).
In contrast, K17 immunostaining was detectable at a mean level approximately five-fold less in the cells throughout the basaloid strands of all the desmoplastic trichoepithelioma specimens analyzed. able in the lesions of trichoblastoma and ranged from absent or low in some specimens to patchy and even diffuse in other specimens (Table 1 ).
Discussion
We found that K17 is strongly expressed histologically throughout BCC lesions. This expression was present intensely throughout the lesional tissue, regardless of tumor subtype. The results indicate that the intensity of K17 expression may not necessarily correlate with the more-aggressive behavior generally associated with the morpheaform BCC variant. Thus, the morpheaform subtype of tumors we studied did not have a correspondingly higher expression of K17, although morpheaform BCC has an expression pattern strikingly different from that of desmoplastic trichoepithelioma, and K17 is able to highlight distinct and subtle tumor cells in the dermis of morpheaform BCC specimens. By assisting in defining the surgical margin on a Mohs section and highlighting subtle tumor strands or by definitively differentiating morpheaform BCC from desmoplastic trichoepithelioma, our novel findings could prove useful in clinical and surgical management.
In previous efforts to identify immunohistochemical methods to distinguish between morpheaform BCC and desmoplastic trichoepithelioma, some differences in the immunostaining patterns have been noted. Expression of the anti-apoptotic protein bcl-2 has been reported throughout BCC lesions while only being positive in the outer rim of epithelium in desmoplastic trichoepithelioma. 32 In addition, it has been reported that a comparison of immunostaining for androgen receptors and cytokeratin 20 (CK20) can help in making this dis- tinction. Thus, BCC is usually positive for androgen receptors and negative for CK20, whereas the reverse immunostaining pattern is found in desmoplastic trichoepithelioma. 33, 34 Nevertheless, despite several investigations, there has been no single immunohistochemical stain to reliably and uniformly differentiate these tumors. Because K17 does not partially stain desmoplastic trichoepithelioma (unlike bcl-2) and does not require a comparison of two antigens (androgen receptors and CK20), it may represent an advance in the ease of distinguishing these tumors. This advance may be especially important when the tumor biopsy sample is small.
As our results indicate, K17 immunostaining of trichoblastoma was variable, ranging from nearly absent in some specimens to diffuse in others. The reason for this finding is unclear, but the variable expression may be related to the maturational stage of each neoplasm. In addition, even in cases in which K17 immunostaining of this tumor was graded as diffuse, the intensity was much less than found in BCC specimens (Table 1) .
Overall, our work shows that the K17 antibody immunolabels BCC with a strong signal and minimal background. K17 expression may also differentiate BCC from such benign look-alikes as desmoplastic trichoepithelioma and trichoblastoma. These differentiating features of K17 may have useful applications for dermatopathology and dermatologic surgery.
We found that K17 immunostaining could be accomplished in frozen and paraffin-embedded sections. There are at least three applications of the K17 immunostaining when used in formalin-fixed, paraffin-embedded tissue. First, it can be used for margin evaluation of tissue after standard surgical excision of morpheaform BCC. Second, K17 expression can be used for margin evaluation of en face sections during slow Mohs, when Mohs sections are evaluated as formalin-fixed, paraffinembedded tissue. Third, K17 immunostaining can be used diagnostically, in ambiguous basaloid proliferations, when the differential diagnosis includes BCC, desmoplastic trichoepithelioma, and trichoblastoma. Rapid methods of K17 immunolabeling in Mohs surgery will further enhance the diagnostic value of K17 expression. 35 In summary, we determined the diagnostic utility of K17 immunolabeling. Our data showed that K17 successfully immunolabeled BCC. It did so with high intensity, little background, and the ability to detect BCC cells at the margin. The K17 expression was helpful in labeling BCC, whereas benign lookalikes such as trichoepithelioma and trichoblastoma had low levels of intensity or distribution. 
